Please login to the form below

Not currently logged in


This page shows the latest KOLs news and features for those working in and with pharma, biotech and healthcare.

GSK to reverse ‘no KOLs’ policy, admitting it has hit marketing

GSK to reverse ‘no KOLs’ policy, admitting it has hit marketing

Company seeking to revive lacklustre marketing performance. GlaxoSmithKline is to reverse its ban on paying healthcare professionals and key opinion leaders (KOLs), admitting that the policy has hit awareness of its ... GSK says it will now return to

Latest news

  • Taming the Monster Taming the Monster

    physicians and KOLs.

  • Signal strength Signal strength

    Certainly, as companies seek to build reputation and trust amongst KOLs, medical affairs teams will be central to demonstrating the transparency, scientific rigour and medical accountability that should underpin every communication

  • Harnessing the unrivalled power of key opinion leaders Harnessing the unrivalled power of key opinion leaders

    Indeed, many pharma companies have been shown to wait until phase III has started before approaching KOLs. ... For example, some KOLs may be experts in clinical trial design while others might excel in public speaking.

  • Back to the future Back to the future

    For example, market access and KOL management are secondary to channel management and branding.

  • Connected Healthcare Connected Healthcare

    Despite the inexorable shift to digital, Cello's research has found that information received face-to-face from peers, key opinion leaders (KOLs), pharma sales representatives and sponsored conferences remain the

More from news
Approximately 2 fully matching, plus 105 partially matching documents found.

Latest Intelligence

  • Breaking from tradition - social media at medical congresses Breaking from tradition - social media at medical congresses

    4. Provide a platform for others.Could you tick both the value-added and partnership boxes by helping your Key Opinion Leaders (KOLs) to develop their profile using your corporate social ... Increasingly, as well as planning offline symposia and speaking

  • The social dilemma: is it time for pharma to join the party?

    One potential area is Key Opinion Leader (KOL) development. Pharma builds much of its engagement model around KOLs. ... Tapas Mukherjee. But is the industry’s emphasis on KOLs dictating – and perhaps even restricting – modern HCP engagement?

  • Is anybody listening? Is anybody listening?

    As with all engagement initiatives, marketers need to work as hard to identify COLs (Consumer Opinion Leaders) and POLs (Patient Opinion Leaders) as they’ve historically done to identify clinical KOLs.

  • Nudge-nudge, think-think Nudge-nudge, think-think

    It’s a classic ‘nudge’. The principle is at the root of KOL work – but it applies equally to patients.

  • Developing advocacy in the pharmaceutical industry Developing advocacy in the pharmaceutical industry

    Programme types are multiple and varied, and if you have a KOL or group of KOLs in mind, it is important to match your programme with their strengths and career status. ... But if you or your company is new to a therapy area, you may wish to use KOL

More from intelligence
Approximately 7 fully matching, plus 34 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 6 fully matching, plus 46 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...